Tumors of various histological origins show abundant infiltration of myeloid cells from early
stages of disease progression. These cells have a profound impact on antitumor immunity
and influence fundamental processes that underlie malignancy, including neoangiogenesis,
sustained cancer cell proliferation, metastasis and therapy resistance. For these reasons,
development of therapeutic approaches to deplete or reprogram myeloid cells in cancer is
an emerging field of interest. However, knowledge about the heterogeneity of myeloid cells …